ADHD has a major effect on the prefrontal cortex of the brain. Credit: Manu5.

Aevi Genomic Medicine has completed patient enrolment for Part B of its ASCEND clinical trial.

The Phase II study will evaluate the safety and efficacy of AEVI-001 in pediatric and adolescent patients with attention deficit hyperactivity disorder (ADHD).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The adaptive, six-week, genomically guided trial comprises parts A and B.

Part A of the trial will investigate a mGluR mutation positive genetic subset of paediatric and adolescent patients, while Part B will examine paediatric and adolescent patients with ADHD without metabotropic glutamate receptor (mGluR) mutations.

In August, Aevi completed enrolling patients for Part A, which features subjects who have one of the eight specific gene mutations implicated in glutamatergic signalling and neuronal connectivity.

Part B includes patients who do not have copy number variants (CNVs) in any of the specific gene mutation(s) implicated in glutamatergic signalling and neuronal connectivity.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“AEVI-001 is a unique, oral, non-stimulant activator/modulator of mGluRs, with the potential to help many patients.”

The subjects are expected to be randomised in 1:1 ratio into one of two treatment groups, AEVI-001 or placebo.

Topline results from Parts A and B of Aevi’s ASCEND trial are scheduled to be available by January next year.

The company plans to conduct individual and pooled analysis for both parts simultaneously, and will provide data on the design of a planned Phase III programme.

Aevi Genomic Medicine chief scientific officer Garry Neil said: “Attention deficit hyperactivity disorder affects millions of paediatric and adolescent patients and despite a number of drugs on the market today, we believe treatment is suboptimal for many patients.

“AEVI-001 is a unique, oral, non-stimulant activator/modulator of mGluRs, with the potential to help many patients and their families.”

AEVI-001 contains improved pharmacokinetic and metabolic profiles, and crosses the blood brain barrier.

The investigational product is yet to receive approval from the US Food and Drug Administration, or any other regulatory agencies.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact